Treatment of Hepatitis D — A Future Role for Combination Therapy

Hepatitis D virus (HDV) infection is the most serious form of viral hepatitis, with an accelerated clinical course and heightened risks of cirrhosis and liver cancer.1 No therapies for HDV infection have been approved by the Food and Drug Administration (FDA), which has made the management of this disease challenging for decades. However, the tide has turned, with several new drugs under study. The goal of therapy is to achieve HDV eradication, with the very best treatment being one that would achieve clearance of both HDV and hepatitis B surface antigen (HBsAg), yielding a functional cure of both HDV and . . .